BofA/Merrill analyst Geoff Meacham reinstated coverage of Biogen with an Underperform rating and $200 price target, citing competitive risks for Spinraza in SMA, price/share erosion in MS, and a pipeline focused on high risk/reward assets.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here